
    
      This is a single-arm, open-label and exploratory clinical study of Anlotinib Hydrochloride
      Capsules combined with Sintilimab injection in the treatment of advanced Hepatocellular
      Carcinoma (HCC).In oder to observe and evaluate the efficacy and safety of Anlotinib
      Hydrochloride Capsules combined with Sintilimab injection.subjects with pathological
      confirmed Hepatocellular Carcinoma will be enrolled.21 days as a treatment cycle, Anlotinib
      12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be
      administered until disease progressioncor un-tolerable toxicity. Anlotinib will be
      administered until disease progression. If anlotinib is not tolerated, the dose can be
      reduced to 10mg or 8mg ,until un-tolerable toxicity again.
    
  